Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53

1.

Is solifenacin succinate safe and effective for the treatment of overactive bladder?

Eilber KS.

Nat Clin Pract Urol. 2008 Mar;5(3):128-9. doi: 10.1038/ncpuro1040. Epub 2008 Jan 15. No abstract available.

PMID:
18195721
2.

Solifenacin succinate for the treatment of overactive bladder.

Hoffstetter S, Leong FC.

Expert Opin Drug Metab Toxicol. 2009 Mar;5(3):345-50. doi: 10.1517/17425250902762866 . Review.

PMID:
19331596
3.

The cost utility of solifenacin in the treatment of overactive bladder.

Hakkaart L, Verboom P, Phillips R, Al MJ.

Int Urol Nephrol. 2009;41(2):293-8. doi: 10.1007/s11255-008-9448-2. Epub 2008 Aug 15.

PMID:
18704742
4.

Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial.

Cardozo L, Hessdörfer E, Milani R, Arañó P, Dewilde L, Slack M, Drogendijk T, Wright M, Bolodeoku J; SUNRISE Study Group..

BJU Int. 2008 Nov;102(9):1120-7. doi: 10.1111/j.1464-410X.2008.07939.x. Epub 2008 Oct 6.

5.

Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial.

Toglia MR, Serels SR, Laramée C, Karram MM, Nandy IM, Andoh M, Seifeldin R, Forero-Schwanhaeuser S.

Postgrad Med. 2009 Sep;121(5):151-8. doi: 10.3810/pgm.2009.09.2062.

PMID:
19820284
6.

A cost-utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome.

Speakman M, Khullar V, Mundy A, Odeyemi I, Bolodeoku J.

Curr Med Res Opin. 2008 Aug;24(8):2173-9. doi: 10.1185/03007990802234829. Epub 2008 Jun 18.

PMID:
18565239
7.

Solifenacin for overactive bladder in women unsuccessfully treated with immediate release oxybutynin: a pilot study.

Wong C, Duggan P.

J Obstet Gynaecol. 2009 Jan;29(1):31-4. doi: 10.1080/01443610802628726.

PMID:
19280492
8.

Urodynamic parameters after solifenacin treatment in men with overactive bladder symptoms and detrusor underactivity.

Ronchi P, Gravina GL, Galatioto GP, Costa AM, Martella O, Vicentini C.

Neurourol Urodyn. 2009;28(1):52-7. doi: 10.1002/nau.20586.

PMID:
18671288
9.

Solifenacin for therapy resistant overactive bladder.

Hoebeke P, De Pooter J, De Caestecker K, Raes A, Dehoorne J, Van Laecke E, Vande Walle J.

J Urol. 2009 Oct;182(4 Suppl):2040-4. doi: 10.1016/j.juro.2009.05.100. Epub 2009 Aug 20.

PMID:
19695608
10.
11.

Cost-effectiveness analysis of solifenacin flexible dosing in patients with overactive bladder symptoms in four Nordic countries.

Milsom I, Axelsen S, Kulseng-Hansen S, Mattiasson A, Nilsson CG, Wickstrøm J.

Acta Obstet Gynecol Scand. 2009;88(6):693-9. doi: 10.1080/00016340902849738.

PMID:
19384673
12.

Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial.

Karram MM, Toglia MR, Serels SR, Andoh M, Fakhoury A, Forero-Schwanhaeuser S.

Urology. 2009 Jan;73(1):14-8. doi: 10.1016/j.urology.2008.08.485. Epub 2008 Nov 8.

PMID:
18995887
13.

Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout mice.

Ito Y, Oyunzul L, Yoshida A, Fujino T, Noguchi Y, Yuyama H, Ohtake A, Suzuki M, Sasamata M, Matsui M, Yamada S.

Eur J Pharmacol. 2009 Aug 1;615(1-3):201-6. doi: 10.1016/j.ejphar.2009.04.068. Epub 2009 May 13.

PMID:
19446545
14.

Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.

Chancellor MB, Zinner N, Whitmore K, Kobashi K, Snyder JA, Siami P, Karram M, Laramée C, Capo' JP Jr, Seifeldin R, Forero-Schwanhaeuser S, Nandy I.

Clin Ther. 2008 Oct;30(10):1766-81. doi: 10.1016/j.clinthera.2008.10.011.

PMID:
19014833
15.

Impact of solifenacin on resource utilization, work productivity and health utility in overactive bladder patients switching from tolterodine ER.

Zinner N, Noe L, Rasouliyan L, Marshall T, Seifeldin R.

Curr Med Res Opin. 2008 Jun;24(6):1583-91. doi: 10.1185/03007990802081766. Epub 2008 Apr 17.

PMID:
18423103
16.

Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency.

Kaplan SA, McCammon K, Fincher R, Fakhoury A, He W.

J Urol. 2009 Dec;182(6):2825-30. doi: 10.1016/j.juro.2009.08.023. Epub 2009 Oct 17.

PMID:
19837435
17.

Pharmacological effects of solifenacin on human isolated urinary bladder.

Masunaga K, Yoshida M, Inadome A, Murakami S, Sugiyama Y, Satoji Y, Maeda Y, Ueda S.

Pharmacology. 2008;82(1):43-52. doi: 10.1159/000127840. Epub 2008 Apr 24.

PMID:
18434763
18.
19.

Solifenacin at 3 years: a review of efficacy and safety.

Pelman RS, Capo JP Jr, Forero-Schwanhaeuser S.

Postgrad Med. 2008 Jul;120(2):85-91. doi: 10.3810/pgm.2008.07.1795. Review.

PMID:
18654073
20.

[Assessment of symptoms severity in patients with overactive bladder].

Al'-Shukri SKh, Kuz'min IV.

Urologiia. 2008 Nov-Dec;(6):37-40. Russian.

PMID:
19248597

Supplemental Content

Support Center